undamentalytics Newsletter
Sign in

Insight Molecular Diagnostics Inc. revenue

Insight Molecular Diagnostics Inc.'s revenue was $4.1m in fiscal 2025, up 115.6% on the year before. Since fiscal 2020 ($1.2m) it has grown at a compound 27.2% a year. Over the last twelve months it was $1.7m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue01,2162,1989581,5031,8814,0551,670
Growth on the year before——+80.8%−56.4%+56.9%+25.1%+115.6%—
Gross profit—−6391,420−184137402,298807

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Laboratory Services $4M 99.4% ▲ 116.8%
Kitted Products $24,000 0.6% —
Laboratory Developed Test Services $0 0.0% ▼ 100.0%
Geography
Region Revenue Share YoY
United States $4M 99.4% ▲ 140.9%
Europe $24,000 0.6% ▲ 33.3%
United Kingdom $0 0.0% ▼ 100.0%
Asia Pacific $0 0.0% ▼ 100.0%

From Insight Molecular Diagnostics Inc.'s 10-K filed March 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Insight Molecular Diagnostics Inc. $1.7m -60.8% 14.9%
Seastar Medical Holding Corp $1.7m 123.6% —
Femasys Inc $2.3m 21.9% 24.3%
Pulse Biosciences, Inc. $1.2m 100.0% —
Volitionrx LTD $2.5m 86.3% 68.0%
Icecure Medical Ltd. $3.4m 2.7% —

Compare with peers

Head to head: ICU vs IMDXFEMY vs IMDXIMDX vs PLSE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Insight Molecular Diagnostics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Insight Molecular Diagnostics Inc.